• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alector Reports First Quarter 2024 Financial Results and Provides Business Update

    5/8/24 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email

    Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024

    Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors

    $562.1 million in cash, cash equivalents and investments provide runway through 2026

    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 2024, Alector's cash, cash equivalents and investments totaled $562.1 million.

    "Continuing the momentum built through the first quarter, Alector is well positioned to have an impactful year, supported by an extended cash runway that carries the company through 2026," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "We are advancing our maturing pipeline, including our pivotal Phase 3 trial of latozinemab in FTD-GRN. In early Alzheimer's disease, we are now investigating two clinical candidates. The data readout from the INVOKE-2 Phase 2 clinical trial of AL002 is expected in the fourth quarter, while enrollment continues in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226. Additionally, the potential of our versatile blood-brain barrier technology, Alector Brain Carrier, to enhance brain penetrance of selected product candidates is exciting and provides opportunities to further expand our clinical pipeline for the long term. With the most advanced TREM2-activating and PGRN-modulating product candidates in clinical trials and a robust early-stage pipeline, we remain dedicated to developing medicines for individuals suffering from brain disorders."

    Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development at Alector, added, "In addition to these encouraging research and development updates, Alector continues to strengthen its leadership team with executive and Board appointments. We are excited to recognize the addition of Neil Berkley to our executive team as our Chief Business Officer. Neil has over 20 years of corporate development, business development and strategic planning experience, spanning large pharma to small biotechs. Additionally, we are pleased to welcome Dr. Errol De Souza and Mark Altmeyer to our Board of Directors. As our late-stage clinical assets progress closer toward potential FDA approval and commercialization, we look forward to leveraging their collective experience."

    Recent Clinical Updates

    Immuno-Neurology Portfolio

    Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226) Being Developed in Collaboration with GSK

    • The pivotal, randomized, double-blind, placebo-controlled INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN) is ongoing after reaching full enrollment in October 2023. The trial has a treatment duration of 96 weeks.
    • Enrollment is ongoing in the PROGRESS-AD global Phase 2 clinical trial of AL101/GSK4527226 in early Alzheimer's disease (AD), with dosing initiated in February 2024. AL101 is an investigational human monoclonal antibody (mAb) designed to block and downregulate the sortilin receptor to elevate the level of progranulin (PGRN) in the brain in a manner that is similar to latozinemab but with different pharmacokinetic (PK) and pharmacodynamic (PD) properties. Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson's disease.
    • Alector and GSK plan to present a poster on the design of the AL101 Phase 2 trial at the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia from July 28 to August 1, 2024. The poster is entitled, "PROGRESS-AD: a Phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti-sortilin monoclonal antibody, in patients with early Alzheimer's disease."

    TREM2 Program (AL002) Being Developed in Collaboration with AbbVie

    • The INVOKE-2 Phase 2 clinical trial of AL002 is fully enrolled, and data from the trial are anticipated in the fourth quarter of 2024. INVOKE-2, a randomized, double-blind, placebo-controlled, dose-ranging study, is designed to evaluate the efficacy and safety of AL002 in slowing disease progression in individuals with early AD. AL002 is a novel investigational humanized mAb that binds to TREM2 to increase TREM2 signaling and, thereby, is hypothesized to improve the functionality of microglia. It is the most advanced TREM2-activating product candidate in clinical development worldwide.
    • The company expects to report baseline characteristics data from the Phase 2 trial of AL002 at a medical conference later this year, providing insights into the early AD patient population enrolled, including key baseline health metrics and disease characteristics.
    • AbbVie has an exclusive option to globally develop and commercialize AL002. AbbVie's exercise of that option would prompt a $250 million payment to Alector.

    Early Research Pipeline

    • Alector continues to advance Alector Brain Carrier (ABC), a proprietary, versatile blood-brain barrier (BBB) technology platform, which is being applied selectively to the company's next-generation product candidates and research pipeline.
    • Alector will host a virtual research and development event on June 18, 2024, to discuss the company's ABC technology platform. The event will include a presentation from a leading scientific expert, offering insights into emerging technologies for BBB modulation and discussing future directions and opportunities in the field. The event will be webcast live on the Investor section of the company's website at https://investors.alector.com.
    • Details of the event are as follows:



      Crossing the Blood-Brain Barrier: Advancing the Next Generation of Alector Neurodegenerative Therapies ​
      • June 18, 2024, at 12 pm Pacific Daylight Time / 3 pm Eastern Daylight Time

    Corporate

    • In March 2024, Alector expanded its executive leadership team with the appointment of Neil Berkley, M.S., M.B.A., as Chief Business Officer. Mr. Berkley is responsible for driving strategic growth and maximizing partnership opportunities at the company. He brings over 20 years of extensive experience in corporate development, business development and strategic planning across a spectrum of biopharmaceutical companies.
    • In March 2024, Alector strengthened its Board of Directors with the appointments of Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A.

      • Dr. De Souza is an esteemed leader in research and development, as well as a seasoned business executive, whose expertise is focused on the discovery and development of therapeutics targeting central nervous system (CNS) disorders.
      • Mr. Altmeyer has more than 35 years of experience leading successful drug development and commercialization efforts as a biopharmaceutical executive, with a focus on CNS disorders and oncology.

    First Quarter 2024 Financial Results

    Revenue. Collaboration revenue for the quarter ended March 31, 2024, was $15.9 million, compared to $16.5 million for the same period in 2023. The decrease was primarily due to a decrease in collaboration revenue recognized for the AL001 program.

    R&D Expenses. Total research and development expenses for the quarter ended March 31, 2024, were $45.2 million, compared to $51.9 million for the quarter ended March 31, 2023. The decrease was mainly driven by the Company's prioritization on selected late-stage programs and a decrease in personnel-related costs.

    G&A Expenses. Total general and administrative expenses for the quarter ended March 31, 2024, were $14.4 million, compared to $14.8 million for the quarter ended March 31, 2023.

    Net Loss. For the quarter ended March 31, 2024, Alector reported a net loss of $36.1 million, or $0.38 per share, compared to a net loss of $45.9 million, or $0.55 net loss per share, for the same period in 2023.

    Cash Position. Cash, cash equivalents, and investments were $562.1 million as of March 31, 2024. In January 2024, Alector further strengthened its balance sheet with the completion of a follow-on financing issuing 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses. Management expects that this will be sufficient to fund current operations through 2026.

    2024 Guidance. Management is reiterating its guidance for the year ending 2024. The company continues to anticipate collaboration revenue to be between $60 million and $70 million, total research and development expenses to be between $210 million and $230 million, and total general and administrative expenses to be between $60 million and $70 million.

    About Alector

    Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector's immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer's disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, planned and ongoing preclinical studies and clinical trials, expected milestones, expectations of our collaborations, expected benefits of Dr. De Souza's and Mr. Altmeyer's appointment to our Board of Directors and Mr. Berkley's appointment as our Chief Business Officer, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on May 8, 2024, with the Securities and Exchange Commission ("SEC"), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.



    Selected Consolidated Balance Sheet Data

    (in thousands)
     
     March 31,   December 31, 
     2024   2023 
    Cash, cash equivalents, and marketable securities$562,083  $548,861 
    Total assets 635,494   621,827 
    Total current liabilities (excluding deferred revenue) 91,565   94,973 
    Deferred revenue (including current portion) 277,927   293,820 
    Total liabilities 456,587   487,669 
    Total stockholders' equity 178,907   134,158 





    Consolidated Statement of Operations Data

    (in thousands, except share and per share data)
     
      Three Months Ended

    March 31,
     
     2024

      2023

     
    Collaboration revenue$15,893  $16,549 
    Operating expenses:       
    Research and development 45,167   51,887 
    General and administrative 14,434   14,777 
    Total operating expenses 59,601   66,664 
    Loss from operations (43,708)  (50,115)
    Other income, net 7,636   5,159 
    Loss before income taxes (36,072)  (44,956)
    Income tax expense 7   901 
    Net loss$(36,079) $(45,857)
    Net loss per share, basic and diluted$(0.38) $(0.55)
    Shares used in computing net loss per share basic and diluted 93,810,177   83,102,296 

    Alector Contacts:

    Alector

    Katie Hogan

    202-549-0557

    [email protected]

    1AB (media)

    Dan Budwick

    973-271-6085 

    [email protected]

    Argot Partners (investors)

    Laura Perry

    212.600.1902

    [email protected]



    Primary Logo

    Get the next $ALEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    More analyst ratings

    $ALEC
    Financials

    Live finance-specific insights

    See more
    • Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

      2/26/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and follo

      2/19/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

      Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLO

      1/13/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Alector Reports First Quarter 2024 Financial Results and Provides Business Update

      Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

      5/8/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

      3/29/22 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 

      2/7/22 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      12/6/24 5:30:28 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/12/24 7:21:57 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/7/24 12:41:31 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Reports First Quarter 2025 Financial Results and Provides Business Update

      Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda

      5/8/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York) Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat A webcast of each conference presentation will be available on the "Events & Presentations" page w

      5/6/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ALEC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Alector Inc.

      10-Q - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:15:17 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:10:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Alector Inc.

      DEFA14A - Alector, Inc. (0001653087) (Filer)

      4/24/25 4:02:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 31% to 66,666 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      5/2/25 6:00:09 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Grasso Marc sold $26,547 worth of shares (18,091 units at $1.47), decreasing direct ownership by 5% to 312,560 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:13 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Rosenthal Arnon sold $59,176 worth of shares (40,330 units at $1.47), decreasing direct ownership by 2% to 2,466,744 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:18 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alector downgraded by Mizuho with a new price target

      Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $2.50 from $9.00 previously

      12/17/24 7:23:27 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by Stifel with a new price target

      Stifel downgraded Alector from Buy to Hold and set a new price target of $4.00

      12/16/24 6:41:43 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by BofA Securities with a new price target

      BofA Securities downgraded Alector from Neutral to Underperform and set a new price target of $1.00 from $9.00 previously

      12/4/24 7:19:54 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care